8-K: Connect Biopharma's Partner Simcere Submits New Drug Application for Rademikibart in China for Atopic Dermatitis

Connect Biopharma announced that its exclusive licensee in China, Simcere Pharmaceutical, has submitted a New Drug Application for rademikibart to the National Medical Products Administration of China for the treatment of atopic dermatitis in adults and adolescents.

Summary

• Connect Biopharma's collaborator, Simcere Pharmaceutical Co., Ltd., has submitted a New Drug Application (NDA) for rademikibart to the National Medical Products Administration of China (NMPA).
• The NDA is for the treatment of atopic dermatitis (AD) in adults and adolescents.
• Connect and Simcere entered into an exclusive license and collaboration agreement for rademikibart in China in 2023.
• Under the agreement, Connect is eligible to receive up to approximately $110 million in remaining milestone payments.
• Connect is also eligible for tiered royalties up to low double-digit percentages on net sales in Greater China.
• The atopic dermatitis market in China is estimated to have 70 million patients.
• Rademikibart is a fully human monoclonal antibody targeting interleukin-4 receptor alpha (IL-4R), designed to block IL-4 and IL-13 functions and the Th2 inflammatory pathway.
• Connect Biopharma retains rights to rademikibart in all markets outside Greater China and is conducting global studies for asthma and COPD.

Sentiment

Score: 8

Explanation: The submission of an NDA is a major positive regulatory milestone, indicating significant progress towards commercialization in a large market. The potential for substantial milestone payments and royalties is also very positive. While regulatory approval is not guaranteed, this is a strong step forward.

Positives

• Submission of a New Drug Application (NDA) for rademikibart in China marks a significant regulatory milestone, indicating progress towards potential commercialization.
• The atopic dermatitis market in China is substantial, with an estimated 70 million patients, representing a considerable opportunity for rademikibart.
• Connect Biopharma is eligible to receive up to approximately $110 million in remaining milestone payments from Simcere, providing potential future non-dilutive funding.
• Connect Biopharma is also eligible for tiered royalties up to low double-digit percentages on net sales in Greater China, offering a long-term revenue stream if approved.
• Rademikibart is described as a 'potentially best in class next generation IL-4R antibody' by management, highlighting its therapeutic potential.
• The drug's mechanism of action (blocking IL-4 and IL-13 via IL-4R) targets a key inflammatory pathway (Th2), which is relevant for multiple inflammatory diseases.

Risks

• Unexpected safety or efficacy data or results observed during clinical trials or in data readouts.
• Occurrence of adverse safety events.
• Risks of unexpected costs, delays, or other unexpected hurdles in drug development.
• Difficulties in collaborating with other companies.
• Successful development and/or commercialization of alternative product candidates by competitors.
• Changes in expected or existing competition.
• Delays in or disruptions to business or clinical trials due to geopolitical changes or other external factors.
• Unexpected litigation or other disputes.
• Uncertainty regarding whether the NMPA approves Simcere's NDA and the timing of any such approval.
• Uncertainty regarding whether Connect Biopharma becomes eligible for any additional milestone or royalty payments.

Future Outlook

The company anticipates potential NMPA approval for rademikibart in China, which could lead to eligibility for additional milestone and royalty payments. Management remains committed to advancing rademikibart for a range of inflammatory diseases, including atopic dermatitis, asthma, and chronic obstructive pulmonary disease, and sees a significant market opportunity in China for atopic dermatitis.

Management Comments

• Simcere continues to make strong progress in advancing rademikibart in China, our potentially best in class next generation IL-4R antibody.
• Atopic dermatitis remains a large and growing market in China, and rademikibart has the potential to significantly improve the condition for millions of patients.
• Together, we remain committed to advancing rademikibart for the treatment of a range of inflammatory diseases including AD, asthma, and chronic obstructive pulmonary disease.

Industry Context

This announcement highlights the continued global focus on developing novel therapies for inflammatory diseases, particularly atopic dermatitis, which represents a large and growing market, especially in China. The submission of an NDA for an IL-4R antibody positions rademikibart within a competitive landscape of biologics targeting similar pathways for inflammatory conditions. The collaboration with Simcere, a China-focused pharmaceutical company, underscores the strategic importance of local partnerships for market access and regulatory navigation in key regions.

Comparison to Industry Standards

• The development of IL-4R alpha antibodies like rademikibart is a common strategy in the biopharmaceutical industry for treating Th2-mediated inflammatory diseases, with Dupixent (dupilumab) from Regeneron/Sanofi being a leading global benchmark in atopic dermatitis and asthma.
• While specific comparative clinical data is not provided in this filing, the 'potentially best in class' claim suggests an ambition to differentiate rademikibart from existing therapies.
• The market size for atopic dermatitis in China, estimated at 70 million patients, is a significant opportunity, comparable to or exceeding patient populations in other major markets, indicating a strong commercial rationale for the NDA submission.

Stakeholder Impact

• Shareholders: Positive impact due to significant progress towards potential commercialization in a large market, potential for milestone payments and royalties, and validation of the company's pipeline asset.
• Patients (in China): Potential for a new treatment option for atopic dermatitis, addressing a significant unmet medical need for millions of patients.
• Employees: Positive impact from the advancement of a key pipeline asset and the company's strategic progress.
• Simcere Pharmaceutical: Strengthens their pipeline with a potential new therapy for a large market.

Next Steps

• NMPA review and potential approval of the NDA for rademikibart for atopic dermatitis in adults and adolescents in China.
• Potential for Connect Biopharma to become eligible for additional milestone and royalty payments upon regulatory and commercial achievements.
• Continued global studies of rademikibart for the treatment of acute exacerbations of asthma and COPD.

Key Dates

Recommendation

Keywords

Connect Biopharma, CNTB, Simcere Pharmaceutical, Rademikibart, CBP-201, New Drug Application, NDA, NMPA, Atopic Dermatitis, AD, IL-4R, IL-4, IL-13, Th2 inflammatory pathway, China, Biopharmaceutical, Clinical-stage, Inflammatory diseases, Milestone payments, Royalties, Drug development, Regulatory approval